- Home
- IMMX vs MNOV Comparison
IMMX vs MNOV Comparison
Compare IMMX & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- MNOV
- Stock Information
- Founded
- IMMX 2014
- MNOV 2000
- Country
- IMMX United States
- MNOV United States
- Employees
- IMMX N/A
- MNOV N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- MNOV Health Care
- Exchange
- IMMX Nasdaq
- MNOV Nasdaq
- Market Cap
- IMMX 61.1M
- MNOV 68.2M
- IPO Year
- IMMX 2021
- MNOV 2005
- Fundamental
- Price
- IMMX $2.65
- MNOV $1.27
- Analyst Decision
- IMMX Strong Buy
- MNOV Strong Buy
- Analyst Count
- IMMX 1
- MNOV 2
- Target Price
- IMMX $7.00
- MNOV $7.00
- AVG Volume (30 Days)
- IMMX 137.1K
- MNOV 17.6K
- Earning Date
- IMMX 08-11-2025
- MNOV 08-07-2025
- Dividend Yield
- IMMX N/A
- MNOV N/A
- EPS Growth
- IMMX N/A
- MNOV N/A
- EPS
- IMMX N/A
- MNOV N/A
- Revenue
- IMMX N/A
- MNOV N/A
- Revenue This Year
- IMMX N/A
- MNOV N/A
- Revenue Next Year
- IMMX N/A
- MNOV N/A
- P/E Ratio
- IMMX N/A
- MNOV N/A
- Revenue Growth
- IMMX N/A
- MNOV N/A
- 52 Week Low
- IMMX $1.26
- MNOV $1.12
- 52 Week High
- IMMX $3.00
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- IMMX 61.44
- MNOV 40.89
- Support Level
- IMMX $2.16
- MNOV $1.32
- Resistance Level
- IMMX $2.80
- MNOV $1.38
- Average True Range (ATR)
- IMMX 0.17
- MNOV 0.05
- MACD
- IMMX 0.04
- MNOV -0.00
- Stochastic Oscillator
- IMMX 80.00
- MNOV 15.38
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.